GW Pharmaceuticals Buy Hold or Sell Recommendation

GWPH -- USA Stock  

USD 167.66  4.79  2.78%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding GW Pharmaceuticals plc is 'Strong Hold'. Macroaxis provides GW Pharmaceuticals buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding GWPH positions. The advice algorithm takes into account all of GW Pharmaceuticals plc available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from GWPH buy-and-hold prospective. Please also check GW Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Symbol
Execute Advice
Sell GW PharmaceuticalsBuy GW Pharmaceuticals
Strong Hold

Volatility

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

Inapplicable
For the selected time horizon GW Pharmaceuticals plc has a risk adjusted performance of (0.033672), jensen alpha of (0.25), total risk alpha of (0.53), sortino ratio of 0.0 and treynor ratio of (0.13)
Macroaxis provides buy or sell advice on GW Pharmaceuticals plc to complement and cross-verify current analyst consensus on GW Pharmaceuticals. Our buy, hold, or sell suggestion engine determines the entity potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. To make sure GW Pharmaceuticals plc is not overpriced, please check out all GW Pharmaceuticals plc fundamentals including its Cash and Equivalents, Number of Employees and the relationship between Price to Sales and Book Value Per Share . Given that GW Pharmaceuticals plc has Price to Earning of (18.91)X, we strongly advise you confirm GW Pharmaceuticals market performance and probability of bankruptcy to make sure the company can sustain itself this quarter and beyond given your latest risk tolerance and investing horizon.

GW Pharmaceuticals Trading Alerts and Improvement Suggestions

GW Pharmaceuticals generates negative expected return over the last 30 days
The company reported previous year revenue of 62.82M. Net Loss for the year was (268.23M) with loss before overhead, payroll, taxes, and interest of (19.8M).
GW Pharmaceutical currently holds about 521.67M in cash with (290.82M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.98.
Over 82.0% of the company shares are owned by institutional investors

GW Pharmaceuticals current analysts recommendations

Target Median Price224.50
Target Mean Price223.58
Recommendation Mean1.80
Target High Price250.00
Number Of Analyst Opinions12
Target Low Price198.00

GW Pharmaceuticals Returns Distribution Density

Mean Return0.11Value At Risk2.78
Potential Upside2.89Standard Deviation1.79
 Return Density 
      Distribution 

Institutional Investors

Security TypeSharesValue
Rothschild Investment CorpCommon Shares17.7 K3 M
Woodstock CorpCommon Shares5.3 K906 K
Gofen Glossberg LlcCommon Shares2.9 K496 K
Exane DerivativesCommon Shares1.7 K290.1 K
Dubuque Bank Trust CoCommon Shares1.3 K230 K
Cordasco Financial NetworkCommon Shares20034 K
Lenox Wealth Advisors LlcCommon Shares18632 K

GW Pharmaceuticals Greeks

α
Alpha over DOW
=0.25
β
Beta against DOW=0.90
σ
Overall volatility
=1.82
Ir
Information ratio =0.15

GW Pharmaceuticals Volatility Alert

GW Pharmaceuticals plc exhibits very low volatility with skewness of 0.24 and kurtosis of -0.85. However, we advise investors to further study GW Pharmaceuticals plc technical indicators to make sure all market info is available and is reliable.
    
 Better Than Average     
    
 Worse Than Average Compare GW Pharmaceuticals to competition

GW Pharmaceuticals Fundamental Vs Peers

FundamentalsGW PharmaceuticalsPeer Average
Return On Equity(0.66)% (0.31)%
Return On Asset(0.57)% (0.14)%
Operating Margin(440.09)% (5.51)%
Current Valuation4.98B16.62B
Shares Outstanding30.72M571.82M
Shares Owned by Insiders0.62% 10.09%
Shares Owned by Institutions81.95% 39.21%
Number of Shares Shorted3.23M4.71M
Price to Earning(18.91)X28.72X
Price to Book8.29X9.51X
Price to Sales84.46X11.42X
Revenue62.82M9.43B
Gross Profit(19.8M)27.38B
EBITDA(266.22M)3.9B
Net Income(268.23M)570.98M
Cash and Equivalents521.67M2.7B
Cash per Share16.98X5.01X
Total Debt37.13M5.32B
Debt to Equity5.80% 48.70%
Current Ratio7.81X2.16X
Book Value Per Share20.83X1.93K
Cash Flow from Operations(290.82M)971.22M
Short Ratio10.80X4.00X
Earnings Per Share(8.61)X3.12X
Price to Earnings To Growth0.84X4.89X
Number of Employees79118.84K
Beta2.07-0.15
Market Capitalization5.31B19.03B
Total Asset453.18M29.47B
Retained Earnings(475.39M)9.33B
Working Capital369.57M1.48B
Current Asset404.52M9.34B
Current Liabilities34.95M7.9B
   Sale by Alicia Secor of 900 shares of GW Pharmaceuticals [view details]
Search macroaxis.com